# Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)

> **NCT06486441** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Gilead Sciences** · enrollment: 640 (estimated)

## Conditions studied

- Endometrial Cancer

## Interventions

- **DRUG:** Sacituzumab govitecan-hziy
- **DRUG:** Doxorubicin
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT06486441
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-08-28
- **Primary completion:** 2029-06
- **Final completion:** 2029-06
- **Target enrollment:** 640 (ESTIMATED)
- **Last updated:** 2026-01-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06486441

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06486441, "Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)". Retrieved via AI Analytics 2026-06-27 from https://api.ai-analytics.org/clinical/NCT06486441. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*